Xeris Biopharma Holdings, INC Form 4 insider transactions

Steven Pieper, CFO of Xeris Biopharma Holdings, reports the withholding of shares to cover income tax obligations related to vested Restricted Stock Units.

Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, reports the withholding of shares to cover tax obligations and acquisition of shares through the employee stock purchase plan.

Xeris Biopharma's Chief Financial Officer, Steven Pieper, exercised stock options and acquired 19,483 shares of common stock at $1.55 per share on November 22, 2024.

Director John P. Schmid of Xeris Biopharma Holdings, Inc. reports purchasing 4,515 shares of common stock at $2.2474 per share on August 12, 2024.

Director John P. Schmid reports the acquisition of 4,285 shares of Xeris Biopharma Holdings, Inc. at a price of $2.365 per share on August 9, 2024.

Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, reports changes in beneficial ownership due to tax withholding on vested RSUs and participation in the employee stock purchase plan.

Kenneth Erland Johnson, a Senior Vice President at Xeris Biopharma Holdings, reported changes in his beneficial ownership of company stock due to tax withholding on vested RSUs and participation in the employee stock purchase plan.

Steven Pieper, CFO of Xeris Biopharma Holdings, reports the withholding of shares to cover income tax obligations related to RSU vesting.

CEO John Patrick Shannon Jr. reports acquisition of 250,000 shares of common stock and 300,000 stock appreciation rights, along with disposals to cover tax obligations.

Kevin McCulloch, President and COO of Xeris Biopharma Holdings, acquired 150,000 shares of common stock and 200,000 stock appreciation rights on August 1, 2024.

Director John P. Schmid reports acquiring 50,000 shares of Xeris Biopharma Holdings through a restricted stock unit award.

Director Ricki Louise Fairley reports acquisition of 50,000 shares of Xeris Biopharma Holdings, Inc. through a restricted stock unit award and disposal of 135,000 shares.

Director Jeffrey W. Sherman acquired 50,000 shares of Xeris Biopharma Holdings, Inc. through a restricted stock unit award, according to a recent SEC Form 4 filing.

Director Barbara-Jean Anne Bormann-Kennedy acquired 50,000 shares of Xeris Biopharma Holdings, Inc. through a restricted stock unit award.

Director John Johnson acquired 50,000 shares of Xeris Biopharma Holdings, Inc. through a restricted stock unit award.

Marla Persky, a director of Xeris Biopharma Holdings, reports the acquisition of 50,000 restricted stock units and the disposal of 6,370 shares held indirectly through a revocable trust.

Director Garheng Kong acquired 50,000 shares of Xeris Biopharma Holdings common stock through a restricted stock unit award.

Director Dawn Halkuff reports acquisition of 50,000 shares of Xeris Biopharma Holdings common stock through a restricted stock unit award and disposition of 5,410 shares held indirectly through a revocable trust.

Director John P. Schmid reports purchasing 5,400 shares of Xeris Biopharma Holdings at $1.91 per share on May 10, 2024, increasing his total holdings.

Director Jeffrey W. Sherman acquired 6,502 shares of Xeris Biopharma Holdings, Inc. common stock due to the achievement of a Keveyis sales milestone.

Director Garheng Kong acquired 6,474 shares of Xeris Biopharma Holdings, Inc. common stock on March 15, 2024, due to the achievement of a Keveyis sales milestone.

Director John Johnson acquired 89,571 shares of Xeris Biopharma Holdings, Inc. common stock due to the achievement of a Keveyis sales milestone.

Director John Johnson exercised stock options and sold shares of Xeris Biopharma Holdings, Inc. on March 18, 2024.

Director John P. Schmid of Xeris Biopharma Holdings, Inc. reports purchasing 4,500 shares of common stock at $2.16 per share.